JLE

Innovations & Thérapeutiques en Oncologie

MENU

Drug interactions between antiretroviral and chemo-/ targeted therapy Volume 5, issue 6, November-December 2019

Tables

Authors
1 APHM, Hôpital La Timone
Laboratoire de pharmacocinétique et toxicologie
264, rue Saint-Pierre
F-13005 Marseille
France
2 AP-HP, Hôpitaux Universitaires Pitié-
Salpêtrière – Charles Foix
Oncologie médicale
47-83, boulevard de l’hôpital
75013 Paris
France
3 Sorbonne Université
INSERM
Institut Pierre Louis d’épidémiologie et de
santé publique, équipe Theravir
56,boulevard Vincent Auriol
75646
Paris
France
4 Aix Marseille Univ, INSERM 1207, IRD
190, EFS IRBA
Unité des virus émergents
27, boulevard Jean Moulin
France
* Tirés à part

Drug-drug interactions (DDI) between treatments for HIV infection and cancer disease are frequent and often clinically relevant, requiring particular attention to avoid severe acute toxicities or therapeutic failure. Interactions are mainly due to additive toxicities or common metabolic pathways via hepatic enzymes, such as cytochrome P450 enzymes and/or drug transporters. The high potential for DDI, which is widely recognised in classic chemotherapy, remains significant with new targeted cancer therapies, as the majority of these drugs are also substrates, inhibitors and/or inducers of drug transporters and hepatic enzymes. Thus, this highlights the urgent need for their evaluation in HIV-infected patients before starting cancer treatment. For this reason, multidisciplinary staff meetings are strongly advised to discuss the most appropriate therapeutic strategy in order to maintain treatment efficacy and prevent the occurrence of severe acute toxicities, which may be life-threatening.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License